



The new frontier of EPD to provide higher protection from adverse events during TAVI procedures



AorticLab srl Via Ribes, 5, 10010 Colleretto Giacosa TO, Italy



Distributor:



Kardia srl Via Cormons, 18, 20151 Milano, Italy



### 🔄 Engagement Made Easy:

The distal structure of FLOWer is designed for effortless engagement, ensuring a secure and reliable fit with the aorta.

# Efficient Deployment and Intuitive Control:

Adding at most 3 mins to deployment.

## 12 Fr Introducer Compatibility:

Effortless Closure Management compatible with standard, pre-mounted suture-based closure devices.

## **One Design, 3 Sizes:**

The different sizes guarantee a perfect fit with aortas ranging from 25 mm to 39 mm. The correct device size is determined during the pre-procedural CT scan analysis.

SIZE	NOMINAL SIZE (mm)	EXPANSION RANGE (mm) (D1)
FLOWer 28	28	≥ 25 TO 29 (included)
FLOWer 32	32	> 29 TO 34 (included)
FLOWer 36	36	> 34 TO 39 (included)

# FLWer





- Minimal to no interference with existing TAVI delivery systems.
- ->> No need for device-specific ACT adjustments.
- **Gentle on the vascular access site** reducing complications and ensuring a smoother recovery.
- A Minimal thrombogenicity.
- Enhanced tactile sensitivity throughout the deployment process facilitating real-time adjustments for precise and secure positioning.
- **Stability during deployment** with adjustable distal structure and adaptive spine.
- No need for a further access site thanks to the customized pigtail provided with the device.
- Non-traumatic against the aortic wall even during the most complex procedures.



## **Comprehensive Cerebral Protection:**

Advanced filtering technology **can capture debris greater than 60 μm**, significantly reducing the risk of stroke and cerebral complications.

## Beyond the Brain:

**Non-cerebral debris capture and removal**, protecting the brain and peripheral circulation.

# Clinical Efficiency:

- In in vitro studies, simulating human circulation, FLOWer prevented over 99% of microspheres from reaching the brain and captured 74% of them.
- In clinical trials, an average of 420 particles were captured per filter. More than half of these particles were smaller than 150 µm, highlighting FLOWer's capability to intercept even the smallest of threats.
- No access site vascular complication in the clinical trial of over 75 patients.
- Stroke rate within 72 hours in the Nautilus clinical trial: 1.5%.

Sources (1) FLOWer - The Complete Embolic Protection Device – Nautilus Study, EuroPCR 2023. (2) FLOWer Instruction for Use.